Combination Products: How FDA Decides Which Center Reviews Yours

Every combination product sponsor eventually files a document that decides more than it looks like it decides: the Request for Designation. It reads like a jurisdictional formality. It is actually the filing that sets your lead FDA center, your review pathway, your user-fee program, and — for the life of the product — which quality system you run. Sponsors who treat it as paperwork get an outcome. Sponsors who treat it as a case get the outcome they built.

PMOA decides more than the label suggests

A combination product combines a drug, device, or biological product — or more than one — as a single entity, a co-packaged kit, or cross-labeled products meant to be used together. Under 21 CFR 3.2(e), that definition is broad enough to capture drug-eluting devices, prefilled injector-drug combinations, and diagnostic-therapeutic pairings alike. What is not broad is how FDA assigns jurisdiction over one: the primary mode of action, defined at 21 CFR 3.2(m) as the single mode of action expected to make the greatest contribution to the product's overall intended therapeutic effects, decides which center leads.

The algorithm behind the assignment

When the PMOA can be determined with reasonable certainty, the assignment under 21 CFR 3.4 is close to mechanical: a drug PMOA goes to CDER, a biological product PMOA goes to CBER, a device PMOA goes to CDRH. The harder cases — and the ones worth building a strategy around — are the ones where FDA cannot determine the PMOA with reasonable certainty. There, the agency falls back to a documented algorithm: first, which center regulates other combination products that raise similar types and levels of safety and effectiveness questions; failing that, which center has the most relevant expertise to evaluate the most significant safety and effectiveness questions the product raises. Neither fallback asks what the sponsor would prefer. Both reward a sponsor who has already framed, in writing, why its product's questions belong to a particular center's expertise.

• The Office of Combination Products (OCP) coordinates the jurisdictional decision and issues the binding determination — it does not itself review the product, the assigned center does.
• Lead-center assignment is not exclusive expertise. A device-led product with a significant drug constituent can still draw an inter-center consult to the drug center for the questions only that center is positioned to answer.
• The assignment follows the product, not the sponsor's portfolio history. A company whose other products are device-led should not assume a new combination product inherits that center by association.
• Classification drives the applicable regulatory pathway — NDA/BLA versus 510(k)/PMA/De Novo — and therefore the applicable user-fee program and review timeline.

The RFD does not describe a decision that was already made. It builds the record FDA's decision will be based on. Sponsors who file it as a formality are handing that record to someone else to write. Why PMOA strategy starts before the filing

Pre-RFD just got more demanding

Before committing to a binding RFD, sponsors can request informal, non-binding feedback through the Pre-RFD process. FDA revised its Pre-RFD guidance in November 2025, replacing the prior final guidance from February 2018. The update is not cosmetic: OCP now expects sponsors to first check FDA's existing classification precedent and published jurisdictional resources before requesting a Pre-RFD meeting, and it is more prescriptive about what the submission itself needs to contain. A Pre-RFD built the way sponsors got used to filing under the 2018 guidance is now more likely to draw a request for additional information before OCP will engage — which costs the calendar time a Pre-RFD is meant to save.

The jurisdictional decision does not end at the letter granting your designation. A device-led product still runs its quality system under the QMSR that now governs 21 CFR Part 820; a drug-led product runs Part 210/211 cGMP. Part 4 Subpart A lets a sponsor apply a single, primary CGMP system — drug or device — supplemented by specific provisions of the other, rather than operating two full quality systems in parallel. Which system that ends up being was decided the day PMOA was determined, which is exactly why the RFD deserves the same rigor as a Q-Submission meeting package rather than the administrative afterthought it is often treated as. Getting the quality system implementation question resolved early avoids rebuilding it after the center assignment is already final.